Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24247544 | 0.76 | BRD4 (1.00) | BRD4BRD2BRD3 | |
| SCHEMBL22734477 | 0.68 | TP53 (0.36) | MAPTMEN1KMT2ATP53 | |
| SCHEMBL22734659 | 0.68 | KMT2A (0.37) | BRD4MAPTMEN1KMT2ATP53 | |
| SCHEMBL22735698 | 0.67 | KMT2A (0.38) | KMT2ATP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL22735922 | 0.67 | BRD4 (0.58) | BRD4MAPTTP53 | |
| SCHEMBL22735689 | 0.66 | TP53 (0.51) | BRD4MAPTTP53 | |
| SCHEMBL22735677 | 0.65 | KMT2A (0.36) | MEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL22735938 | 0.65 | CTSK (0.38) | — | |
| SCHEMBL22735702 | 0.65 | CTSK (0.38) | — | |
| SCHEMBL22734504 | 0.63 | CTSS (0.35) | MAPTKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | BET1, BRD4, BRD3 | BRD4 2/4885MAPT 1856/4885MEN1 3935/4885 |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | BET1, BRD4, BRD3 | BRD4 2/4885MAPT 1820/4885MEN1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.